vTv Therapeutics: Samsara sells 61,287 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
At vTv Therapeutics Inc. (VTVT), reporting person Samsara BioCapital, L.P. sold 61,287 shares of Class A common stock at $17.60 per share in a block trade on November 12, 2026. The shares were held for the exclusive benefit of limited partners who had redeemed their interests in Samsara LP; Samsara BioCapital GP, LLC and Srinivas Akkaraju had no economic interest in them.
Srinivas Akkaraju reported beneficial ownership of 412,654 shares, or 9.9%, with the percentage rounded down. The calculation used 4,011,465 shares outstanding as of November 5, 2026, and gave effect to warrants and options exercisable within 60 days, including 6,399 stock options. Warrant exercises are subject to a 9.99% beneficial ownership blocker.
Key Figures
Key Terms
Pre-Funded Warrants financial
Common Warrants financial
Beneficial Ownership Blockers financial
block trade financial
beneficially owned financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of VTVT did Srinivas Akkaraju report beneficially owning?
What limits exercise of Samsara's VTVT warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.